We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+1.03%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$269M
AUM Growth
-$21.2M
Cap. Flow
-$10M
Cap. Flow %
-3.73%
Top 10 Hldgs %
26.35%
Holding
168
New
26
Increased
41
Reduced
37
Closed
31

Top Buys

Rank Stock Value
1
META icon
Meta Platforms (Facebook)
META
+$3.11M
2
GH icon
Guardant Health
GH
+$2.65M
3
JANX icon
Janux Therapeutics
JANX
+$2.45M
4
APLS
Apellis Pharmaceuticals
APLS
+$2.19M
5
GEHC icon
GE HealthCare
GEHC
+$1.85M

Top Sells

Rank Stock Value
1
CTLT
CATALENT, INC.
CTLT
+$4.58M
2
CPRI icon
Capri Holdings
CPRI
+$3.3M
3
AMGN icon
Amgen
AMGN
+$3.25M
4
CART icon
Maplebear
CART
+$3.2M
5
GEV icon
GE Vernova
GEV
+$2.47M

Sector Composition

Rank Sector Weight
1 Healthcare 43.86%
2 Technology 16.73%
3 Consumer Discretionary 7.18%
4 Communication Services 5.42%
5 Industrials 4.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADBE icon
101
Adobe
ADBE
$105B
$1.2M 0.45%
2,700
+900
+50% +$446K
CZR icon
102
Caesars Entertainment
CZR
$6.07B
$1.18M 0.44%
+35,200
New +$1.39M
CORZ icon
103
Core Scientific
CORZ
$6.3B
$1.14M 0.42%
81,300
-51,500
-39% -$761K
ARVN icon
104
Arvinas
ARVN
$586M
$1.11M 0.41%
58,001
– –
VRNA
105
DELISTED
Verona Pharma
VRNA
$1.1M 0.41%
23,739
– –
CRBP icon
106
Corbus Pharmaceuticals
CRBP
$183M
$888K 0.33%
75,292
– –
PRAX icon
107
Praxis Precision Medicines
PRAX
$10.2B
$843K 0.31%
10,951
– –
ASND icon
108
Ascendis Pharma A/S
ASND
$16.6B
$836K 0.31%
+6,072
New +$798K
KROS icon
109
Keros Therapeutics
KROS
$209M
$825K 0.31%
52,107
– –
CNTA
110
DELISTED
Centessa Pharmaceuticals
CNTA
$772K 0.29%
46,116
– –
NTRA icon
111
Natera
NTRA
$45.5B
$764K 0.28%
4,828
+1,388
+40% +$202K
XNCR icon
112
Xencor
XNCR
$1.64B
$734K 0.27%
+31,942
New +$734K
OCUL icon
113
Ocular Therapeutix
OCUL
$2.11B
$728K 0.27%
85,241
+20,214
+31% +$197K
TERN
114
DELISTED
Terns Pharmaceuticals
TERN
$726K 0.27%
130,966
– –
TCOM icon
115
Trip.com Group
TCOM
$29.1B
$711K 0.26%
10,356
+800
+8% +$52.9K
DNTH icon
116
Dianthus Therapeutics
DNTH
$6.11B
$684K 0.25%
31,387
+11,579
+58% +$298K
MDGL icon
117
Madrigal Pharmaceuticals
MDGL
$12.2B
$682K 0.25%
2,211
– –
CYTK icon
118
Cytokinetics
CYTK
$10.7B
$671K 0.25%
14,261
+4,206
+42% +$218K
KRYS icon
119
Krystal Biotech
KRYS
$9.62B
$661K 0.25%
+4,217
New +$748K
SLNO
120
DELISTED
Soleno Therapeutics
SLNO
$645K 0.24%
14,344
+3,259
+29% +$169K
CGON icon
121
CG Oncology
CGON
$6.75B
$640K 0.24%
22,305
+6,571
+42% +$225K
ITCI
122
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$626K 0.23%
7,496
– –
GPCR icon
123
Structure Therapeutics
GPCR
$3.72B
$476K 0.18%
17,561
-14,157
-45% -$502K
GERN icon
124
Geron
GERN
$1.04B
$451K 0.17%
127,284
– –
CATX icon
125
Perspective Therapeutics
CATX
$357M
$441K 0.16%
138,350
– –
3 4
5
6 7

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $361M AUM 134.26% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return
PPG
Peak Planning Group Centennial, Colorado $361M AUM 22.01% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

HighVista Strategies's Q4 2024 Portfolio in Review

As of Q4 2024, HighVista Strategies held 168 positions worth $269M, down 7.3% from $290M the previous quarter. Its ten largest holdings account for 26% of the portfolio.

HighVista Strategies withdrew a net $10M in Q4 2024, closing 31 positions and reducing 37 holdings. Its most notable exit was CATALENT, INC., an estimated $4.58M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, down from 46% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, HighVista Strategies opened a new position in Meta Platforms (Facebook) worth $3.1M.

  • HighVista Strategies's largest Q4 2024 buy was Meta Platforms (Facebook): 5,300 shares worth $3.1M.
  • HighVista Strategies added most to Janux Therapeutics in Q4 2024, an estimated $2.45M increase.
  • HighVista Strategies's biggest Q4 2024 reduction was GE Vernova, cutting an estimated $2.47M.
  • HighVista Strategies fully exited CATALENT, INC. in Q4 2024, selling an estimated $4.58M.
  • HighVista Strategies's ten largest holdings make up 26% of its $269M portfolio in Q4 2024.
  • HighVista Strategies opened 26 new positions and closed 31 in Q4 2024.
  • HighVista Strategies's portfolio value fell 7.3% quarter-over-quarter to $269M.

Based on HighVista Strategies's 13F filing for Q4 2024, filed 14 Feb 2025.